EuroBiotech—More Articles of Note


> Lytix Biopharma rejigged its board of directors ahead of a planned IPO. The changes leave the cancer biotech with a more equal gender split, a requirement for publicly listed companies in its native Norway. Release

> Roche moved its AC Immune-partnered Alzheimer’s candidate into phase 2. The companies are developing the anti-Tau antibody, RG6100, for use in patients with prodromal to mild Alzheimer's disease. Presentation (PDF)

> Antabio raised €7.3 million ($8.7 million). The series A round equips the French biotech to take its inhibitor of bacterial metallo beta-lactamases up to the end of phase 1. Statement


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Ablynx set the terms on its $150 million IPO and accompanying $25 million private placement. The listing gives the Belgian biotech a $1.5 billion market cap. Release 

> Silence Therapeutics stepped up its legal action against Alnylam and The Medicines Company. Statement

> Redx revealed it is edging closer to the end of its bankruptcy ordeal. A court is due to hear its application to be rescued as a going concern next week. Release

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.